Results 151 to 160 of about 47,580 (341)

Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

, 2023
Amr El Zawily, Frederick S. Vizeacoumar, Renuka Dahiya, Sara L. Banerjee, Kalpana K. Bhanumathy, Hussain Elhasasna, Glinton Hanover, Jessica C. Sharpe, Malkon G. Sanchez, Paul Greidanus, R. Greg Stacey, Kyung‐Mee Moon, Ilya Alexandrov, Juha P. Himanen, Dimitar B. Nikolov, Humphrey Fonge, Aaron P. White, Leonard J. Foster, Bingcheng Wang, Behzad M. Toosi, Nicolas Bisson, Tajib A. Mirzabekov, Franco J. Vizeacoumar, Andrew Freywald   +23 more
openalex   +1 more source

Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract—the B Cell Side

Allergy, EarlyView.
ABSTRACT Allergic diseases are on the rise worldwide, driven by respiratory epithelial barrier dysfunction that promotes sensitization to inhalant allergens such as pollen, dust mites, pet dander, and fungal spores. These antigens trigger IgE‐mediated immune responses that lead to diseases such as allergic rhinitis (AR) and asthma.
Ola Grimsholm, Mohammed Zghaebi, Bita Hambrecht, Tanja Kalic, Christopher C. Udoye, Rudolf Manz, Barbara Bohle, Katarzyna M. Sitnik, Julia Eckl‐Dorna, Heimo Breiteneder   +9 more
wiley   +1 more source

Tumour progression shows decrease in PD‐L1 expression in matched metastases/primary uveal melanomas

Acta Ophthalmologica, EarlyView.
Abstract Purpose Immune checkpoint inhibitors (ICI) have revolutionised the treatment of several malignancies. However, the results of ICI therapy remain unsatisfactory in metastatic uveal melanoma (UM). We analysed the expression of PD1, PD‐L1, T‐cell and macrophage markers in a set of matched primary and metastatic UM in an attempt to better ...
Maria Chiara Gelmi, Gulçin Gezgin, Ellen Kapiteijn, T. H. Khanh Vu, Martine J. Jager, Robert M. Verdijk   +5 more
wiley   +1 more source

Supplementary Figure S11 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies

, 2023
Gabrielle Leclercq-Cohen, Nathalie Steinhoff, Llucia Albertí Servera, Sina Nassiri, Sabrina Danilin, Emily Piccione, Emilio Yángüez, Tamara Hüsser, Sylvia Herter, Stephan Schmeing, Petra Gerber, Petra Schwalie, Johannes Sam, Stefanie Briner, Sylvia Jenni, Roberta Bianchi, Marlene Biehl, Floriana Cremasco, Katerina Apostolopoulou, Hélène Haegel, Christian Klein, Pablo Umaña, Marina Bacac   +22 more
openalex   +1 more source

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [PDF]

, 2021
Fatih M. Uckun, Tara L. Lin, Alice S. Mims, Prapti A. Patel, Cynthia Lee, Anoush Shahidzadeh, Paul J. Shami, Elizabeth H. Cull, Christopher R. Cogle, Justin M. Watts   +9 more
openalex   +1 more source

bispecific antibody

Citation: 'bispecific antibody' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.12951 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms ...
openaire   +1 more source

Bispecific antibodies in follicular lymphoma

Haematologica
Bispecific antibodies, specifically anti-CD20 T-cell engaging constructs, are poised to alter the treatment paradigm of multiple B-cell malignancies, including follicular lymphoma. Two CD20xCD3 bispecific antibodies, mosunetuzumab and epcoritamab, are now approved in the United States for third-line or later treatment of follicular lymphoma.
Imran A. Nizamuddin, Nancy L. Bartlett
openaire   +3 more sources

Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B‐cell lymphoma patients

British Journal of Haematology, EarlyView.
Summary The response to salvage chemotherapy in relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) is poor, and data on circulating tumour deoxyribonucleic acid (ctDNA) in this setting are limited. We evaluated ctDNA dynamics in 29 patients with relapsed or refractory DLBCL who received platinum‐based salvage chemotherapy at the University
Yujie Zhong, Johanna Bult, Nick Veltmaat, Filipe Montes de Jesus, Laurens Sillje, Joost Kluiver, Anke van den Berg, Wouter Plattel, Arjan Diepstra, Marcel Nijland   +9 more
wiley   +1 more source

Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody [PDF]

, 2023
Natascha Stergiou, Thomas Wuensche, Maxime Schreurs, Iris Mes, Mariska Verlaan, Esther Kooijman, Albert D. Windhorst, Lone Helboe, Sandra Vergo, Søren Christensen, Ayodeji A. Asuni, Allan Jensen, Guus A.M.S. van Dongen, Benny Bang‐Andersen, Daniëlle J. Vugts, Wissam Beaino   +15 more
openalex   +1 more source

Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma

Cancer Science, EarlyView.
IDO expression in stromal cells was upregulated by MM cells via the JAK–STAT1–NF‐κB–IRF1 signaling pathway. JAK inhibitor abolished IDO and IRF1 upregulation. ABSTRACT Stromal cells are an essential component of the tumor microenvironment (TME) in multiple myeloma (MM). Indoleamine 2,3‐dioxygenase 1 (IDO), an enzyme that metabolizes tryptophan (Trp) to
Toru Ebina, Masaki Ri, Yoshiaki Marumo, Tomoyuki Nakamura, Hirokazu Sasaki, Yoshiko Oshima, Takahiro Nakashima, Shinya Hagiwara, Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Kazufumi Yamagata, Kohmei Kubo, Hirokazu Komatsu, Hirotake Sakuraba, Shinsuke Iida   +18 more
wiley   +1 more source